세계의 웨어러블 주사기 시장 : 디바이스 유형별, 사용 성별, 치료 영역별, 주요 지역별-업계 동향 및 예측(-2035년)

Wearable Injectors Market by Type of Device, Usability, Therapeutic Area and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

US $ 4,799 ￦ 6,609,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,639,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 14,596,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 24,788,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 웨어러블 주사기 시장 규모는 2035년까지 예측 기간 동안 9%의 연평균 복합 성장률(CAGR)로 확대될 전망이며, 현재의 43억 달러에서 2035년까지 121억 달러로 성장할 것으로 예측됩니다.

최근 몇 년동안 세계에서 만성 질환의 이환율이 증가하고 있습니다. 신경질환, 심혈관질환, 만성통증, 종양성질환 등의 장기간에 걸친 임상증상은 현대의 헬스케어 시스템과 그러한 질환으로 고통받는 사람들에게 큰 부담을 주고 있는 것으로 나타나고 있습니다. 현재의 치료법에는 처방된 약제를 경구 및 비경구 투여하는 방법이 있습니다. 이러한 선택사항 중 비경구 투여가 가장 일반적인 방법입니다. 그러나 비경구 투여는 빈번한 투여, 투여 오류, 바늘 찔림 손상 발생, 미생물 오염 위험 등 환자의 편의성에 있어 몇 가지 과제가 있습니다.

최근 몇 년동안 제약 업계에서 자동 주사기, 웨어러블 주사기 및 펜형 주사기와 같은 새로운 약물전달 장치의 출현으로 많은 기술적 진보가 나타났습니다. 대용량 웨어러블 인젝터는 투여 프로세스를 간소화함으로써 복약 애드히어런스를 향상시킨다는 것이 증명되어 주목할 만합니다. 또한 고급 웨어러블 인젝터에는 폭넓은 투여 옵션과 내장된 안전 기구 등 몇 가지 이점이 있습니다. 그 결과, 웨어러블 인젝터는, 재택 간호 환경에서 약제의 피하 투여에 적합한 선택사항이 되고 있습니다. 더 많은 환자가 기존 약물 전달에서 사용자 친화적인 대체 수단으로 이동하고 있기 때문에 대용량 웨어러블 주사기 시장은 향후 큰 폭의 성장을 이룰 가능성이 높습니다.

인슐린 배달용 대용량 웨어러블 주사기는 전 세계 45개사가 제조하고 있습니다. 이러한 주사기의 60%는 기초 용량과 볼러스 용량을 모두 배달할 수 있는 패치 펌프 주사기입니다.

이 보고서는 세계의 웨어러블 주사기 시장을 조사했으며, 시장 개요와 함께 장치 유형별, 사용 성별, 치료 영역별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.

목차

제1장 서문

제2장 조사 방법

제3장 경제 및 기타 프로젝트 특유의 고려 사항

제4장 주요 요약

제5장 서문

제6장 비인슐린 약용 대용량 웨어러블 주사기 : 현재 시장 상황

제7장 비인슐린 약용 대용량 약제 및 디바이스 병용 제품 : 현재 시장 상황

제8장 인슐린 약용 대용량 웨어러블 주사기 : 현재 시장 상황

제9장 제품 경쟁력 분석

제10장 대용량 웨어러블 주사기 개발 기업 : 기업 프로파일

제11장 약제 및 디바이스 병용 제품 : 디바이스 프로파일

• 장의 개요
• 3 mL Micropump (Furosemide)
• 3M hMTS(Adalimumab)
• D-mine Pump(Apomorphine)
• FUROSCIX(R) On-body Infusor(Furosemide)
• Herceptin sc Injection(Herceptin)
• ND0612H Belt Pump(Levodopa/Carbidopa)
• ND0612L Belt Pump(Levodopa/Carbidopa)
• ND0612L Next Generation Patch Pump(Levodopa/Carbidopa)
• ND0701(Apomorphine)
• ND0901(Levodopa/Carbidopa)
• Neulasta OnPro On-Body Injector(Neulasta or Pegfilgrastim)
• Pushtronex System(Repatha or Evolocumab)
• SMT-201(Ketorolac)
• SMT-301(Bupivacaine)
• LUTREPULSE System(Lutrepulse)
• Trevyent(Treprostinil)
• ULTOMRIS Smart Dose Injector(Ravulizumab)

제12장 파트너십 및 협업

제13장 주요 인수 타겟

제14장 특허 분석

제15장 대용량 웨어러블 주사기: 유망한 약물 후보

제16장 임상시험 분석

제17장 자금 조달 및 투자 분석

제18장 사례 연구 : 디바이스 개발 공급망에서 수탁 제조 기관의 역할

제19장 의료기기의 규제와 상환의 정세

제20장 시장 영향 분석 : 촉진요인, 억제요인, 기회, 과제

제21장 비인슐린용 대용량 웨어러블 주사기 시장 규모 및 기회 분석

제22장 인슐린용 대용량 웨어러블 주사기 시장 규모 및 기회 분석

제23장 SWOT 분석

제24장 결론

제25장 주요 인사이트

• 장의 개요
• Qlibrium
• Enable Injections
• Subcuject
• scPharmaceuticals
• Elcam Medical
• West Pharmaceutical Services
• Ypsomed
• Debiotech
• Eitan Medical

제26장 부록 1 : 표 형식의 데이터

제27장 부록 2 : 기업 및 단체 일람

AJY

영문 목차

영문목차

WEARABLE INJECTORS MARKET: OVERVIEW

As per Roots Analysis, the global wearable injectors market is estimated to grow from USD 4.3 billion in the current year to USD 12.10 billion by 2035, at a CAGR of 9% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Device

• Patch Pump / Injectors
• Infusion Pump / Injectors

Usability

• Disposable
• Reusable

Therapeutic Area

• Autoimmune Disorders
• Cardiovascular Disorders
• Metabolic Disorders
• Neurological Disorders
• Oncological Disorders
• Other Disorders

Key Geographical Regions

• North America
• Europe
• Asia
• Latin America
• Middle East and North Africa

WEARABLE INJECTORS MARKET: GROWTH AND TRENDS

The last few years have witnessed a rising incidence of chronic illnesses across the globe. Long term clinical conditions, such as neurological disorders, cardiovascular disorders, chronic pain and oncological disorders, have been shown to impose a significant burden on the modern healthcare system and those who suffer from such diseases. The current treatment options include administration of prescribed medications through oral and parenteral routes. Of these options, parenteral administration of drugs is the most prevalent method. However, parenteral administration poses several challenges for patient convenience, such as frequent dosing, dosing errors, occurrence of needlestick injuries and risk of microbial contamination.

In recent years, the pharmaceutical industry has witnessed many technological advancements with the emergence of novel drug delivery devices, such as autoinjectors, wearable injectors and pen injectors. It is worth highlighting that large volume wearable injectors have proven to improve medication adherence by simplifying the administration process. In addition, advanced wearable injection devices offer several advantages, such as wide range of dosing options and in-built safety mechanisms. As a result, wearable injectors have become the preferred choice for subcutaneous administration of drugs in home-care settings. The large volume wearable injectors market is likely to witness a substantial growth in the future as more patients shift from conventional to user-friendly drug delivery alternatives.

WEARABLE INJECTORS MARKET: KEY INSIGHTS

The report delves into the current state of the global wearable injectors market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Presently, over 40 wearable injectors and drug device combinations are available or being developed by close to 25 manufacturers; a relatively larger proportion of these players were established before 2000.

2. Nearly 90% of the large volume wearable injectors that can deliver non-insulin drugs targeting multiple disease indications have been commercialized.

3. 45 large volume wearable injectors are being manufactured for insulin delivery by players across the globe; ~60% of these injectors are patch pumps / injectors having the capability to deliver both basal and bolus doses.

4. The market landscape is highly fragmented, featuring the presence of both new entrants and established players based across different geographical regions; close to 45% of such players are mid-sized companies.

5. In pursuit of gaining a competitive edge, companies engaged in the manufacturing of large volume wearable injectors are presently focusing on the integration of advanced features into their respective product offerings.

6. The rising interest in this domain is also reflected by the number of partnerships that have been inked in the recent past, involving both international and local stakeholders.

7. Close to 300 patents have been filed / granted for large volume wearable injectors by industry and non-industry players to protect the intellectual property generated within this field.

8. An evaluation of both marketed / pipeline products reveals that there are a variety of drugs / product candidates that are likely to be considered for administration via large volume wearable injectors.

9. Nearly 160 clinical trials have been registered to evaluate the safety and efficiency of large volume wearable injectors for insulin and non-insulin drugs; majority are these studies are conducted in the US.

10. Considering the enormous opportunities associated with large volume wearable injectors, investors have actively extended funds, amounting to USD 1.4 billion, in the last few years.

11. In order to deal with the complexities associated with manufacturing and assembly of large volume wearable injectors, device developers are known to frequently engage the services of contract service providers.

12. Owing to the advantages offered by large volume wearable injectors for the delivery of insulin and non-insulin drugs, the market is anticipated to witness a steady growth in the foreseen future.

13. Driven by the growing demand for large volume wearable injectors for the delivery of non-insulin drugs, the overall market is anticipated to grow at an annualized rate of over 10% in the coming decade.

14. Growth in the large volume wearable injectors market for non-insulin drugs is anticipated to be primarily driven by the rising demand across various regions; North America is expected to capture the highest share by 2035.

15. The opportunity within the large volume wearable injectors market for insulin drugs is likely to be well-distributed across different type of device, usability and geographies.

WEARABLE INJECTORS MARKET FOR NON-INSULIN DRUGS: KEY SEGMENTS

Currently, Patch Pumps / Injectors Occupies the Largest Share of the Large Volume Wearable Injectors Market for Non-Insulin Drugs

Based on the type of device, the global large volume wearable injectors market for non-insulin drugs is segmented into patch pump / on body injectors and wearable infusion pump. It is worth highlighting that the market for infusion pumps / injectors for non-insulin drugs is likely to grow at a relatively higher CAGR, during the forecast period.

Reusable Devices Segment is the Fastest Growing Segment of the Large Volume Wearable Injectors Market for Non-Insulin Drugs

Based on the usability, the global large volume wearable injectors market for non-insulin drugs is segmented into disposable devices and reusable devices. It is worth highlighting that the market for reusable devices for non-insulin drugs is likely to grow at a relatively higher CAGR, during the forecast period.

At Present, Oncological Disorders Occupies the Largest Share of the Large Volume Wearable Injectors Market for Non-Insulin Drugs

Based on the therapeutic area, the market is segmented into autoimmune disorders, cardiovascular disorders, metabolic disorders, neurological disorders, oncological disorders and other disorders. While oncological disorders account for a relatively higher market share, it is worth highlighting that the autoimmune disorders segment is expected to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, and Latin America. It is worth highlighting that, over the years, the market in Middle East and North Africa is expected to grow at a higher CAGR.

WEARABLE INJECTORS MARKET FOR INSULIN DRUGS: KEY SEGMENTS

Patch Pumps / Injectors Segment is the Fastest Growing Segment of the Large Volume Wearable Injectors Market for Insulin Drugs

Based on type of device, the global large volume wearable injectors market for insulin drugs is segmented into patch pump / on body injectors and wearable infusion pump. It is worth highlighting that the market for patch pumps / injectors for insulin drugs is likely to grow at a relatively higher CAGR, during the forecast period.

Currently, Reusable Devices Segment Occupies the Largest Share of the Large Volume Wearable Injectors Market for Insulin Drugs

Based on usability, the global large volume wearable injectors market for insulin drugs is segmented into disposable devices and reusable devices. It is worth highlighting that the market for reusable autoinjectors for insulin drugs is likely to dominate the market in the forthcoming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia, Middle East and North Africa, and Latin America. It is worth highlighting that, over the years, the market in Asia is expected to grow at a higher CAGR.

Example Players in the Wearable Injectors Market

• CCBio
• CeQur
• Debiotech
• E3D Elcam Drug Delivery Devices
• Eli Lilly
• Enable Injections
• Gerresheimer
• Insulet
• Medtronic
• Medtrum Technologies
• Pharmasense
• Roche
• Sonceboz
• Weibel CDS
• West Pharmaceuticals
• SOOIL Development

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

• Chief Executive Officer, Qlibrium
• Chief Executive Officer, Enable Injections
• Chief Executive Officer, Subcuject
• Former President and Chief Executive Officer, scPharmaceuticals
• Vice President and Chief Scientist, Elcam Medical
• Former Vice President and General Manager (Biologics), West Pharmaceutical Services
• Engineering Project Manager / Senior System Engineer, Debiotech
• Vice President, Marketing and Alliance Management, Eitan Medical

WEARABLE INJECTORS MARKET: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the wearable injectors market, focusing on key market segments, including [A] type of device, [B] usability, [C] therapeutic area and [D] key geographical regions.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.
• Market Landscape of Wearable Injectors for the Delivery of Non-Insulin Drugs: A comprehensive evaluation of wearable injectors for the delivery of non-insulin drugs, considering various parameters, such as [A] status of development, [B] type of device, [C] usability, [D] type of dose, [E] type of drug container, [F] mode of drug filling, [G] container volume (mL), [H] route of administration, [I] mode of injection, [J] mechanism of action, [K] type of technology, [L] availability of connectivity feature, [M] type of compatible drug, [N] compatibility with high viscosity drugs and [O] therapeutic areas. In addition, the chapter presents the market landscape of companies manufacturing large volume wearable injectors for non-insulin drug delivery, including information on their [P] year of establishment, [Q] company size (in terms of number of employees), and [R] location of headquarters.
• Market Landscape of Wearable Injection Device and Drug Combinations for the Delivery of Non-Insulin Drugs: A comprehensive evaluation of wearable injection device and drug combinations for the delivery of non-insulin drugs, considering various parameters, such as [A] status of development, [B] type of device, [C] type of drug container, [D] container volume (mL), [E] route of administration, [F] mode of injection, [G] type of compatible drug, [H] mechanism of action / driving force, [I] type of technology and [J] therapeutic area. In addition, the chapter presents the market landscape of companies manufacturing drug-device combinations for non-insulin drug delivery, including information on their [A] year of establishment, [B] company size (in terms of number of employees), and [C] location of headquarters.
• Market Landscape of Wearable Injectors for the Delivery of Insulin Drugs: A comprehensive evaluation of wearable injectors for the delivery of insulin drugs, considering various parameters, such as [A] status of development, [B] type of device, [C] usability, [D] type of dose, [E] container volume (mL), [F] type of diabetes, [G] type of combination insulin, [H] period of use (days), [I] type of device control feature, [J] availability of interoperable devices, [K] availability of continuous glucose monitoring (CGM) / blood glucose meters (BGM) system, [L] availability of automatic insulin delivery (AID) / artificial pancreas, [M] type of automated insulin delivery feature (AID), [N] availability of connectivity feature and [O] waterproof capabilities. In addition, the chapter presents the market landscape of companies manufacturing large volume wearable injectors for insulin delivery, including information on their [P] year of establishment, [Q] company size (in terms of number of employees), and [R] location of headquarters.
• Product Competitiveness Analysis: A comprehensive competitive analysis of various wearable injectors, examining factors such as [A] company strength, [B] product competitiveness and [C] company size.
• Company Profiles: In-depth profiles of key industry players developing wearable injectors, focusing on [A] company overviews, [B] financial information (if available), [C] product portfolio, [D] an insightful recent development and [E] an informed future outlook.
• Product Profiles: A list of tabulated profiles of wearable drug device combination products featuring [A] drug specifications, [B] mechanism of action, [C] current status of development, [D] dosage frequency and [E] information on sales (if available).
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2015, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] type of partner, [D] type of device, [E] most active players (in terms of number of partnerships), [F] and [G] geography.
• Key Acquisition Targets: A detailed analysis of the key acquisition targets, taking into consideration the historical trend of the acquisition activity of the players that have acquired other firms, since 2000. It offers a means for other industry stakeholders to identify potential acquisition targets.
• Patent Analysis: Detailed analysis of various patents filed / granted related to wearable injectors based on [A] type of patent, [B] patent publication year, [C] jurisdiction, [D] CPC symbol, [E] type of organization, [F] emerging focus area and [G] most active players (based on the number of patents). Additionally, the chapter includes patent benchmarking analysis and insightful patent valuation analysis, highlighting the leading patents (in terms of number of citations).
• Likely Drug Candidates: A list of marketed drugs and therapies, as well as pipeline candidates, that are expected to be developed in conjunction with wearable injectors in the near future. This list is based on a thorough analysis of potential candidates (both marketed and clinical-stage drugs) based on several relevant parameters, such as [A] type of drug molecule, [B] phase of development, [C] indication, [D] dosing frequency, [E] type of therapy, [F] method of administration and [G] route of administration.
• Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various wearable injectors based on parameters like [A] trial recruitment status, [B] trial registration year, [C] trial phase, [D] study design, [E] type of sponsor / collaborator, [F] leading players (based on the number of registered trials), [G] key focus area, [H] therapeutic area and [I] geography.
• Funding and Investment Analysis: A detailed evaluation of the investments made in the this domain, encompassing seed financing, venture capital, capital raised from IPOs, secondary offerings, grants / awards, other equity and debt financing based on several parameters, such as [A] year of funding, [B] amount invested by year, [C] type of funding, [D] type of device, [E] target disease indication, [F] most active players (in terms of number of funding instances and amount invested), [G] leading investors (in terms of number of funding instances) and [H] geography.
• Case Study: A case study examining the role of contract manufacturing organizations in the overall manufacturing process and supply chain of wearable injectors. This study includes details on the services provided by contract service providers for the production of various device components, such as primary containers, infusion sets, adhesives, closures and injection moldings.
• Regulatory Landscape: A discussion on general regulatory guidelines for medical device approvals across North America, Europe, Asia-Pacific and rest of the world. It also includes an insightful multi-dimensional heat map analysis, featuring a comparison of the contemporary regulatory and reimbursement scenarios in key geographies across the globe.
• SWOT Analysis: A SWOT analysis, focusing on key drivers and challenges that are likely to impact the industry's evolution.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Large Volume Wearable Injectors Market Overview
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related Factors
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Introduction to Drug Delivery Devices
• 5.3. Conventional Parenteral Drug Delivery Devices
  • 5.3.1. Needlestick Injuries
  • 5.3.2. Incidence and Cost Burden
  • 5.3.3. Prevention of Needlestick Injuries
  • 5.3.4. Government Legislations for the Prevention of Needlestick Injuries
• 5.4. Emergence of Self-Administration Devices
  • 5.4.1. Key Driving Factors
    • 5.4.1.1. Rising Burden of Chronic Diseases
    • 5.4.1.2. Healthcare Cost Savings
    • 5.4.1.3. Need for Immediate Treatment in Emergency Situations
    • 5.4.1.4. Growing Injectable Drugs Market
    • 5.4.1.5. Need for Improving Medication Adherence
• 5.5. Available Self-Injection Devices
  • 5.5.1. Prefilled Syringes
  • 5.5.2. Pen-Injectors
  • 5.5.3. Needle-Free Injectors
  • 5.5.4. Autoinjectors
  • 5.5.5. Large Volume Wearable Injectors
• 5.6. Regulatory Considerations
  • 5.6.1. Medical Devices
  • 5.6.2. Drug Device Combination Products
• 5.7. Future Perspectives

6. LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Large Volume Wearable Injectors: Overall Market Landscape
• 6.3. Large Volume Wearable Injectors for Non-Insulin Drugs: Overall Market Landscape
  • 6.3.1. Analysis by Status of Development
  • 6.3.2. Analysis by Type of Device
  • 6.3.3. Analysis by Usability
  • 6.3.4. Analysis by Type of Dose
  • 6.3.5. Analysis by Type of Drug Container
  • 6.3.6. Analysis by Mode of Drug Filling
  • 6.3.7. Analysis by Container Volume (mL)
  • 6.3.8. Analysis by Route of Administration
  • 6.3.9. Analysis by Mode of Injection
  • 6.3.10. Analysis by Mechanism of Action / Driving Force
  • 6.3.11. Analysis by Type of Technology
  • 6.3.12. Analysis by Availability of Connectivity Feature
  • 6.3.13. Analysis by Type of Compatible Drug
  • 6.3.14. Analysis by Compatibility with High Viscosity Drugs
  • 6.3.15. Analysis by Therapeutic Area
• 6.4. Large Volume Wearable Injectors for Non-Insulin Drugs: Developer Landscape
  • 6.4.1. Analysis by Year of Establishment
  • 6.4.2. Analysis by Company Size
  • 6.4.3. Analysis by Location of Headquarters
  • 6.4.4. Leading Players: Analysis by Number of Large Volume Wearable Injectors Manufactured for Non-Insulin Drugs

7. LARGE VOLUME DRUG DEVICE COMBINATIONS FOR NON-INSULIN DRUGS: CURRENT MARKET LANDSCAPE

• 7.1. Chapter Overview
• 7.2. Large Volume Drug Device Combinations for Non-Insulin Drugs: Overall Market Landscape
  • 7.2.1. Analysis by Status of Development
  • 7.2.2. Analysis by Type of Device
  • 7.2.3. Analysis by Usability
  • 7.2.4. Analysis by Type of Dose
  • 7.2.5. Analysis by Type of Drug Container
  • 7.2.6. Analysis by Mode of Drug Filling
  • 7.2.7. Analysis by Container Volume (mL)
  • 7.2.8. Analysis by Route of Administration
  • 7.2.9. Analysis by Mode of Injection
  • 7.2.10. Analysis by Type of Compatible Drug
  • 7.2.11. Analysis by Mechanism of Action / Driving Force
  • 7.2.12. Analysis by Type of Technology
  • 7.2.13. Analysis by Therapeutic Area
• 7.3. Large Volume Drug Device Combinations for Non-Insulin Drugs: Developer Landscape
  • 7.3.1. Analysis by Year of Establishment
  • 7.3.2. Analysis by Company Size
  • 7.3.3. Analysis by Location of Headquarters
  • 7.3.4. Leading Players: Analysis by Number of Drug Device Combinations for Non-Insulin Drugs

8. LARGE VOLUME WEARABLE INJECTORS FOR INSULIN DRUGS: CURRENT MARKET LANDSCAPE

• 8.1. Chapter Overview
• 8.2. Large Volume Wearable Injectors for Insulin Drugs: Overall Market Landscape
  • 8.2.1. Analysis by Status of Development
  • 8.2.2. Analysis by Type of Device
  • 8.2.3. Analysis by Usability
  • 8.2.4. Analysis by Type of Dose
  • 8.2.5. Analysis by Mode of Drug Filling
  • 8.2.6. Analysis by Container Volume (mL)
  • 8.2.7. Analysis by Type of Diabetes
  • 8.2.8. Analysis by Type of Combination Insulin
  • 8.2.9. Analysis by Period of Use (Days)
  • 8.2.10. Analysis by Type of Device Control Feature
  • 8.2.11. Analysis by Availability of Interoperable Device
  • 8.2.12. Analysis by Availability of Continuous Glucose Monitoring (CGM) / Blood Glucose Meters (BGM) System
  • 8.2.13. Analysis by Availability of Automatic Insulin Delivery (AID) / Artificial Pancreas
  • 8.2.14. Analysis by Type of Automated Insulin Delivery (AID) Feature
  • 8.2.15. Analysis by Availability of Connectivity Feature
  • 8.2.16. Analysis by Waterproof Capabilities
• 8.3. Large Volume Wearable Injectors for Insulin Drugs: Developer Landscape
  • 8.3.1. Analysis by Year of Establishment
  • 8.3.2. Analysis by Company Size
  • 8.3.3. Analysis by Location of Headquarters
  • 8.3.4. Leading Players: Analysis by Number of Large Volume Wearable Injectors Manufactured for Insulin Drugs

9. PRODUCT COMPETITIVENESS ANALYSIS

• 9.1. Chapter Overview
• 9.2. Assumptions / Key Parameters
• 9.3. Methodology
• 9.4. Product Competitiveness Analysis: Large Volume Wearable Injectors for Non-Insulin Drugs
  • 9.4.1. Products Developed by Players in North America
  • 9.4.2. Products Developed by Players in Europe
  • 9.4.3. Products Developed by Players in Asia and Middle East and North Africa
• 9.5. Product Competitiveness Analysis: Large Volume Drug Device Combinations for Non-Insulin Drugs
  • 9.5.1. Products Developed by Players in North America
  • 9.5.2. Products Developed by Players in Europe
  • 9.5.3. Products Developed by Players in Middle East and North Africa
• 9.6. Product Competitiveness Analysis: Large Volume Wearable Injectors for Insulin Drugs
  • 9.6.1. Products Developed by Players in North America
  • 9.6.2. Products Developed by Players in Europe
  • 9.6.3. Products Developed by Players in Asia and Middle East and North Africa

10. LARGE VOLUME WEARABLE INJECTOR DEVELOPERS: COMPANY PROFILES

• 10.1. Chapter Overview
• 10.2. Key Players Developing Large Volume Wearable Injectors for Non-Insulin Drugs
  • 10.2.1. CCBio
    • 10.2.1.1. Company Overview
    • 10.2.1.2. Product Portfolio
    • 10.2.1.3. Recent Developments and Future Outlook
  • 10.2.2. E3D Elcam Drug Delivery Devices
    • 10.2.2.1. Company Overview
    • 10.2.2.2. Product Portfolio
    • 10.2.2.3. Recent Developments and Future Outlook
  • 10.2.3. Enable Injections
    • 10.2.3.1. Company Overview
    • 10.2.3.2. Product Portfolio
    • 10.2.3.3. Recent Developments and Future Outlook
  • 10.2.4. Gerresheimer
    • 10.2.4.1. Company Overview
    • 10.2.4.2. Financial Information
    • 10.2.4.3. Product Portfolio
    • 10.2.4.4. Recent Developments and Future Outlook
  • 10.2.5. Sonceboz
    • 10.2.5.1. Company Overview
    • 10.2.5.2. Product Portfolio
    • 10.2.5.3. Recent Developments and Future Outlook
  • 10.2.6. Weibel CDS
    • 10.2.6.1. Company Overview
    • 10.2.6.2. Product Portfolio
    • 10.2.6.3. Recent Developments and Future Outlook
  • 10.2.7. West Pharmaceuticals
    • 10.2.7.1. Company Overview
    • 10.2.7.2. Financial Information
    • 10.2.7.3. Product Portfolio
    • 10.2.7.4. Recent Developments and Future Outlook
• 10.3. Key Players Developing Large Volume Wearable Injectors for Insulin Drugs
  • 10.3.1. CeQur
    • 10.3.1.1. Company Overview
    • 10.3.1.2. Product Portfolio
    • 10.3.1.3. Recent Developments and Future Outlook
  • 10.3.2. Debiotech
    • 10.3.2.1. Company Overview
    • 10.3.2.2. Product Portfolio
    • 10.3.2.3. Recent Developments and Future Outlook
  • 10.3.3. Eli Lilly
    • 10.3.3.1. Company Overview
    • 10.3.3.2. Financial Information
    • 10.3.3.3. Product Portfolio
    • 10.3.3.4. Recent Developments and Future Outlook
  • 10.3.4. Insulet
    • 10.3.4.1. Company Overview
    • 10.3.4.2. Financial Information
    • 10.3.4.3. Product Portfolio
    • 10.3.4.4. Recent Developments and Future Outlook
  • 10.3.5. Medtronic
    • 10.3.5.1. Company Overview
    • 10.3.5.2. Financial Information
    • 10.3.5.3. Product Portfolio
    • 10.3.5.4. Recent Developments and Future Outlook
  • 10.3.6. Medtrum Technology
    • 10.3.6.1. Company Overview
    • 10.3.6.2. Product Portfolio
    • 10.3.6.3. Recent Developments and Future Outlook
  • 10.3.7. PharmaSens
    • 10.3.7.1. Company Overview
    • 10.3.7.2. Product Portfolio
    • 10.3.7.3. Recent Developments and Future Outlook
  • 10.3.8. Roche
    • 10.3.8.1. Company Overview
    • 10.3.8.2. Financial Information
    • 10.3.8.3. Product Portfolio
    • 10.3.8.4. Recent Developments and Future Outlook
  • 10.3.9. SOOIL Development
    • 10.3.9.1. Company Snapshot
    • 10.3.9.2. Product Portfolio
    • 10.3.9.3. Recent Developments and Future Outlook

11. DRUG-DEVICE COMBINATIONS: DEVICE PROFILES

• 11.1. Chapter Overview
• 11.2. 3 mL Micropump (Furosemide)
• 11.3. 3M hMTS (Adalimumab)
• 11.4. D-mine Pump (Apomorphine)
• 11.5. FUROSCIX(R) On-body Infusor (Furosemide)
• 11.6. Herceptin sc Injection (Herceptin)
• 11.7. ND0612H Belt Pump (Levodopa / Carbidopa)
• 11.8. ND0612L Belt Pump (Levodopa / Carbidopa)
• 11.9. ND0612L Next Generation Patch Pump (Levodopa / Carbidopa)
• 11.10. ND0701 (Apomorphine)
• 11.11. ND0901 (Levodopa / Carbidopa)
• 11.12. Neulasta OnPro On-Body Injector (Neulasta or Pegfilgrastim)
• 11.13. Pushtronex System (Repatha or Evolocumab)
• 11.14. SMT-201(Ketorolac)
• 11.15. SMT-301 (Bupivacaine)
• 11.16. The LUTREPULSE System (Lutrepulse)
• 11.17. Trevyent (Treprostinil)
• 11.18. ULTOMRIS Smart Dose Injector (Ravulizumab)

12. PARTNERSHIPS AND COLLABORATIONS

• 12.1. Chapter Overview
• 12.2. Partnership Models
• 12.3. Large Volume Wearable Injectors: Partnerships and Collaborations
  • 12.3.1. Analysis by Year of Partnership
  • 12.3.2. Analysis by Type of Partnership
  • 12.3.3. Analysis by Year and Type of Partnership
  • 12.3.4. Analysis by Type of Partner
  • 12.3.5. Analysis by Year of Partnership and Type of Partner
  • 12.3.6. Analysis by Type of Device
  • 12.3.7. Most Active Players: Analysis by Number of Partnerships
  • 12.3.8. Most Active Players: Analysis by Type of Partnership
  • 12.3.9. Analysis by Geography
    • 12.3.9.1. Local and International Agreements
    • 12.3.9.2. Intercontinental and Intracontinental Agreements

13. KEY ACQUISITION TARGETS

• 13.1. Chapter Overview
• 13.2. Scope and Methodology
• 13.3. Scoring Criteria and Key Assumptions
• 13.4. Potential Acquisition Targets: Non-Insulin Drug Delivery Device Developers
• 13.5. Potential Acquisition Targets: Insulin Drug Delivery Device Developers
• 13.6. Concluding Remarks

14. PATENT ANALYSIS

• 14.1. Chapter Overview
• 14.2. Scope and Methodology
• 14.3. Large Volume Wearable Injectors: Patent Analysis
  • 14.3.1. Analysis by Type of Patent
  • 14.3.2. Analysis by Patent Publication Year
  • 14.3.3. Analysis by Jurisdiction
  • 14.3.4. Analysis by CPC Symbols
  • 14.3.5. Word Cloud: Emerging Focus Areas
  • 14.3.6. Analysis by Type of Organization
  • 14.3.7. Most Active Players: Analysis by Number of Patents
• 14.4. Large Volume Wearable Injectors: Patent Benchmarking Analysis
  • 14.4.1. Analysis by Patent Characteristics
• 14.5. Large Volume Wearable Injectors: Patent Valuation Analysis

15. LARGE VOLUME WEARABLE INJECTORS: LIKELY DRUG CANDIDATES

• 15.1. Chapter Overview
• 15.2. Marketed Drugs
  • 15.2.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
  • 15.2.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
  • 15.2.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
  • 15.2.4. Least Likely Candidates for Delivery via Large Volume Wearable Injectors
• 15.3. Clinical stage Drugs
  • 15.3.1.1. Most Likely Candidates for Delivery via Large Volume Wearable Injectors
  • 15.3.1.2. Likely Candidates for Delivery via Large Volume Wearable Injectors
  • 15.3.1.3. Less Likely Candidates for Delivery via Large Volume Wearable Injectors
  • 15.3.1.4. Least Likely Candidates for Delivery via Large Volume Wearable Injectors

16. CLINICAL TRIAL ANALYSIS

• 16.1. Chapter Overview
• 16.2. Scope and Methodology
• 16.3. Large Volume Wearable Injectors: Clinical Trial Analysis
  • 16.3.1. Analysis by Trial Recruitment Status
  • 16.3.2. Analysis by Trial Registration Year
  • 16.3.3. Analysis of Enrolled Patent Population by Trial Registration Year
  • 16.3.4. Analysis by Trial Phase
  • 16.3.5. Analysis of Enrolled Patient Population by Trial Phase
  • 16.3.6. Analysis by Trial Registration Year and Trial Recruitment Status
  • 16.3.7. Analysis by Study Design
  • 16.3.8. Analysis by Type of Sponsor / Collaborator
  • 16.3.9. Leading Players: Analysis by Number of Registered Trials
  • 16.3.10. Word Cloud: Key Focus Areas
  • 16.3.11. Analysis by Therapeutic Area
  • 16.3.12. Most Popular Large Volume Wearable Injectors: Analysis by Number of Registered Trials
  • 16.3.13. Analysis by Geography
  • 16.3.14. Analysis by Trial Recruitment Status and Geography
  • 16.3.15. Analysis of Enrolled Patient Population by Trial Recruitment Status and Geography

17. FUNDING AND INVESTMENT ANALYSIS

• 17.1. Chapter Overview
• 17.2. Types of Funding
• 17.3. Large Volume Wearable Injectors: Funding and Investment Analysis
  • 17.3.1. Analysis by Year of Funding
  • 17.3.2. Analysis of Amount Invested by Year
  • 17.3.3. Analysis by Type of Funding
  • 17.3.4. Analysis by Type of Device
  • 17.3.5. Analysis of Amount Invested by Year and Type of Funding
  • 17.3.6. Analysis of Amount Invested by Type of Device
  • 17.3.7. Analysis by Target Disease Indication
  • 17.3.8. Most Active Players: Analysis by Number of Funding Instances
  • 17.3.9. Most Active Players: Analysis by Amount Invested
  • 17.3.10. Leading Investors: Analysis by Number of Funding Instances
  • 17.3.11. Analysis by Geography

18. CASE STUDY: ROLE OF CONTRACT MANUFACTURING ORGANIZATIONS IN DEVICE DEVELOPMENT SUPPLY CHAIN

• 18.1. Chapter Overview
• 18.2. Device Development Supply Chain
• 18.3. Role of Contract Manufacturing Organizations (CMOs) in Device Development
• 18.4. List of CMOs
  • 18.4.1. Geographical Distribution of CMOs
• 18.5. Medical Devices Design and Development Service Providers

19. REGULATORY AND REIMBURSEMENT LANDSCAPE FOR MEDICAL DEVICES

• 19.1. Chapter Overview
• 19.2. General Regulatory and Reimbursement Guidelines for Medical Devices
• 19.3. Regulatory and Reimbursement Landscape in North America
  • 19.3.1. The US Scenario
    • 19.3.1.1. Regulatory Authority
    • 19.3.1.2. Review / Approval Process
    • 19.3.1.3. Reimbursement Landscape
      • 19.3.1.3.1. Payer Mix
      • 19.3.1.3.2. Reimbursement Process
  • 19.3.2. The Canadian Scenario
    • 19.3.2.1. Regulatory Authority
    • 19.3.2.2. Review / Approval Process
    • 19.3.2.3. Reimbursement Landscape
      • 19.3.2.3.1. Payer Mix
      • 19.3.2.3.2. Reimbursement Process
  • 19.3.3. The Mexican Scenario
    • 19.3.3.1. Regulatory Authority
    • 19.3.3.2. Review / Approval Process
    • 19.3.3.3. Reimbursement Landscape
      • 19.3.3.3.1. Payer Mix
• 19.4. Regulatory and Reimbursement Landscape in Europe
  • 19.4.1. Overall Scenario
    • 19.4.1.1. Overall Regulatory Authority
    • 19.4.1.2. Overall Review / Approval Process
  • 19.4.2. The UK Scenario
    • 19.4.2.1. Regulatory Authority
    • 19.4.2.2. Review / Approval Process
    • 19.4.2.3. Reimbursement Landscape
      • 19.4.2.3.1. Payer Mix
      • 19.4.2.3.2. Reimbursement Process
  • 19.4.3. The French Scenario
    • 19.4.3.1. Regulatory Authority
    • 19.4.3.2. Review / Approval Process
    • 19.4.3.3. Reimbursement Landscape
      • 19.4.3.3.1. Payer Mix
      • 19.4.3.3.2. Reimbursement Process
  • 19.4.4. The German Scenario
    • 19.4.4.1. Regulatory Authority
    • 19.4.4.2. Review / Approval Process
    • 19.4.4.3. Reimbursement Landscape
      • 19.4.4.3.1. Payer Mix
      • 19.4.4.3.2. Reimbursement Process
  • 19.4.5. The Italian Scenario
    • 19.4.5.1. Regulatory Authority
    • 19.4.5.2. Review / Approval Process
    • 19.4.5.3. Reimbursement Landscape
      • 19.4.5.3.1. Payer Mix
      • 19.4.5.3.2. Reimbursement Process
  • 19.4.6. The Spanish Scenario
    • 19.4.6.1. Regulatory Authority
    • 19.4.6.2. Review / Approval Process
    • 19.4.6.3. Reimbursement Landscape
      • 19.4.6.3.1. Payer Mix
      • 19.4.6.3.2. Reimbursement Process
• 19.5. Regulatory and Reimbursement Landscape in Asia-Pacific and Rest of the World
  • 19.5.1. The Australian Scenario
    • 19.5.1.1. Regulatory Authority
    • 19.5.1.2. Review / Approval Process
    • 19.5.1.3. Reimbursement Landscape
      • 19.5.1.3.1. Payer Mix
      • 19.5.1.3.2. Reimbursement Process
  • 19.5.2. The Brazilian Scenario
    • 19.5.2.1. Regulatory Authority
    • 19.5.2.2. Review / Approval Process
    • 19.5.2.3. Reimbursement Landscape
      • 19.5.2.3.1. Payer Mix
      • 19.5.2.3.2. Reimbursement Process
  • 19.5.3. The Chinese Scenario
    • 19.5.3.1. Regulatory Authority
    • 19.5.3.2. Review / Approval Process
    • 19.5.3.3. Reimbursement Landscape
      • 19.5.3.3.1. Payer Mix
      • 19.5.3.3.2. Reimbursement Process
  • 19.5.4. The Indian Scenario
    • 19.5.4.1. Regulatory Authority
    • 19.5.4.2. Review / Approval Process
    • 19.5.4.3. Reimbursement Landscape
      • 19.5.4.3.1. Payer Mix
  • 19.5.5. The Israeli Scenario
    • 19.5.5.1. Regulatory Authority
    • 19.5.5.2. Review / Approval Process
    • 19.5.5.3. Reimbursement Landscape
      • 19.5.5.3.1. Payer Mix
  • 19.5.6. The Japanese Scenario
    • 19.5.6.1. Regulatory Authority
    • 19.5.6.2. Review / Approval Process
    • 19.5.6.3. Reimbursement Landscape
      • 19.5.6.3.1. Payer Mix
      • 19.5.6.3.2. Reimbursement Process
  • 19.5.7. The New Zealand Scenario
    • 19.5.7.1. Regulatory Authority
    • 19.5.7.2. Review / Approval Process
    • 19.5.7.3. Reimbursement Landscape
      • 19.5.7.3.1. Payer Mix
      • 19.5.7.3.2. Reimbursement Process
  • 19.5.8. The Singaporean Scenario
    • 19.5.8.1. Regulatory Authority
    • 19.5.8.2. Review / Approval Process
    • 19.5.8.3. Reimbursement Landscape
      • 19.5.8.3.1. Payer Mix
      • 19.5.8.3.2. Reimbursement Process
  • 19.5.9. The South Korean Scenario
    • 19.5.9.1. Regulatory Authority
    • 19.5.9.2. Review / Approval Process
    • 19.5.9.3. Reimbursement Landscape
      • 19.5.9.3.1. Payer Mix
      • 19.5.9.3.2. Reimbursement Process
  • 19.5.10. The South African Scenario
    • 19.5.10.1. Regulatory Authority
    • 19.5.10.2. Review / Approval Process
    • 19.5.10.3. Reimbursement Landscape
  • 19.5.11. The Taiwanese Scenario
    • 19.5.11.1. Regulatory Authority
    • 19.5.11.2. Review / Approval Process
    • 19.5.11.3. Reimbursement Landscape
      • 19.5.11.3.1. Payer Mix
      • 19.5.11.3.2. Reimbursement Process
  • 19.5.12. The Thailand Scenario
    • 19.5.12.1. Regulatory Authority
    • 19.5.12.2. Review / Approval Process
    • 19.5.12.3. Reimbursement Landscape
• 19.6. Comparison of Regional Regulatory Environment
• 19.7. Concluding Remarks

20. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 20.1. Chapter Overview
• 20.2. Market Drivers
• 20.3. Market Restraints
• 20.4. Market Opportunities
• 20.5. Market Challenges
• 20.6. Conclusion

21. MARKET SIZING AND OPPORTUNITY ANALYSIS FOR LARGE VOLUME WEARABLE INJECTORS FOR NON-INSULIN DRUGS

• 21.1. Chapter Overview
• 21.2. Key Assumptions and Methodology
• 21.3. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Estimates (till 2035) (By Value)
  • 21.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035 (By Value)
    • 21.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
  • 21.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035 (By Value)
    • 21.3.2.1. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
  • 21.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035 (By Value)
    • 21.3.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
  • 21.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geography, 2035 (By Value)
    • 21.3.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.1.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.2.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.3.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 21.3.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.10. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.11. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.12. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.13. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.14. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.15. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.16. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.17. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.18. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 21.3.4.4.19. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
• 21.4. Global Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
  • 21.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Type of Device, 2035 (By Volume)
    • 21.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 21.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
  • 21.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Usability, 2035 (By Volume)
    • 21.4.2.1. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 21.4.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 21.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Therapeutic Area, 2035 (By Volume)
      • 21.4.3.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 21.4.3.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 21.4.3.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 21.4.3.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 21.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 21.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs: Distribution by Geography, 2035 (By Volume)
      • 21.4.4.1. Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.1.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 21.4.4.2. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.2.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 21.4.4.3. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.3.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 21.4.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 21.4.4.4. Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.3. Disposable Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Non-Insulin Drugs in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.5. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Oncological Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.6. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Cardiovascular Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.4.4.4.7. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Autoimmune Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.3.4.4.8. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Neurological Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
        • 21.3.4.4.9. Large Volume Wearable Injectors Market for Non-Insulin Drugs Targeting Other Disorders in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
  • 21.5 Concluding Remarks

22. MARKET SIZING AND OPPORTUNITY ANALYSIS FOR LARGE VOLUME WEARABLE INJECTORS FOR INSULIN

• 22.1. Chapter Overview
• 22.2. Forecast Methodology and Key Assumptions
• 22.3. Global Large Volume Wearable Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
  • 22.3.1. Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2035 (By Value)
    • 22.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 22.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
  • 22.3.2. Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2035 (By Value)
    • 22.3.2.1. Disposable Large Volume Wearable Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 22.3.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
  • 22.3.3. Large Volume Wearable Injectors Market for Insulin: Distribution by Geography, 2035 (By Value)
    • 22.3.3.1. Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.1.3. Disposable Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 22.3.3.2. Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.2.3. Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 22.3.3.3. Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.3.3. Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 22.3.3.4. Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.4.3. Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
    • 22.3.3.5. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.5.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.5.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.5.3. Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
      • 22.3.3.5.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Value)
• 22.4. Global Large Volume Wearable Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
  • 22.4.1. Large Volume Wearable Injectors Market for Insulin: Distribution by Type of Device, 2035 (By Volume)
    • 22.4.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 22.4.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
  • 22.4.2. Large Volume Wearable Injectors Market for Insulin: Distribution by Usability, 2035 (By Volume)
    • 22.4.2.1. Disposable Large Volume Wearable Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 22.4.2.2. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
  • 22.4.3. Large Volume Wearable Injectors Market for Insulin: Distribution by Geography, 2035 (By Value)
    • 22.4.3.1. Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.1.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.1.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.1.3. Disposable Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.1.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in North America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 22.4.3.2. Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.2.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.2.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.2.3. Disposable Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.2.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Europe, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 22.4.3.3. Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.3.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.3.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.3.3. Disposable Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.3.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Asia, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 22.4.3.4. Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.4.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.4.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.4.3. Disposable Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.4.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Latin America, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
    • 22.4.3.5. Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.5.1. Large Volume Wearable Patch Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.5.2. Large Volume Wearable Infusion Pumps / Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.5.3. Disposable Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
      • 22.4.3.5.4. Reusable (Disposable Components) Large Volume Wearable Injectors Market for Insulin in Middle East and North Africa, Historical Trends (since 2017) and Forecasted Estimates (till 2035) (By Volume)
• 22.5 Concluding Remarks

23. SWOT ANALYSIS

• 23.1. Chapter Overview
• 23.2. SWOT Analysis
  • 23.2.1. Strengths
  • 23.2.2. Weaknesses
  • 23.2.3. Opportunities
  • 23.2.4. Threats
• 23.3. Large Volume Wearable Injectors: Future Growth Opportunities
  • 23.3.1. Rising Focus on Self-Administration of Drugs
  • 23.3.2. Possibility of Integration with Mobile Applications
  • 23.3.3. Potential Life Cycle Management Tool
  • 23.3.4. Potential Usability for Multiple Therapeutic Areas

24. CONCLUDING REMARKS

25. EXECUTIVE INSIGHTS

• 25.1. Chapter Overview
• 25.2. Qlibrium
  • 25.2.1. Company Snapshot
  • 25.2.2. Interview Transcript: Larry Albert, Chief Executive Officer
• 25.3. Enable Injections
  • 25.3.1. Company Snapshot
  • 25.3.2. Interview Transcript: Michael Hooven, Chief Executive Officer
• 25.4. Subcuject
  • 25.4.1. Company Snapshot
  • 25.4.2. Interview Transcript: Jesper Roested, Chief Executive Officer
• 25.5. scPharmaceuticals
  • 25.5.1. Company Snapshot
  • 25.5.2. Interview Transcript: Pieter Muntendam, former President and Chief Executive Officer
• 25.6. Elcam Medical
  • 25.6.1. Company Snapshot
  • 25.6.2. Interview Transcript: Menachem Zucker, Vice President and Chief Scientist
• 25.7. West Pharmaceutical Services
  • 25.7.1. Company Snapshot
  • 25.7.2. Interview Transcript: Graham Reynolds, Former Vice President and General Manager, Biologics
• 25.8. Ypsomed
  • 25.8.1. Company Snapshot
  • 25.8.2. Interview Transcript: Anonymous
• 25.9. Debiotech
  • 25.9.1. Company Snapshot
  • 25.9.2. Interview Transcript: Eric Chappel, Engineering Project Manager / Senior System Engineer
• 25.10. Eitan Medical
  • 25.10.1. Company Snapshot
  • 25.10.2. Interview Transcript: Mindy Katz, Vice President, Marketing and Alliance Management

26. APPENDIX 1: TABULATED DATA

27. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료